New York State Common Retirement Fund boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 822,531 shares of the pharmaceutical company’s stock after purchasing an additional 27,484 shares during the period. New York State Common Retirement Fund owned approximately 0.33% of Vertex Pharmaceuticals worth $125,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Achmea Investment Management B.V. lifted its stake in Vertex Pharmaceuticals by 68.0% in the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock worth $1,116,000 after purchasing an additional 3,507 shares during the last quarter. NorthCoast Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth approximately $782,000. Delta Lloyd Asset Management N.V. purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth approximately $3,285,000. Prudential Financial Inc. increased its position in shares of Vertex Pharmaceuticals by 12.8% during the second quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock worth $57,312,000 after acquiring an additional 50,350 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its position in shares of Vertex Pharmaceuticals by 89.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 14,463 shares of the pharmaceutical company’s stock worth $1,863,000 after acquiring an additional 6,836 shares during the period. 93.32% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Incorporated (VRTX) opened at $140.79 on Friday. The stock has a market cap of $36,491.34, a P/E ratio of 240.48, a P/E/G ratio of 3.45 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. Vertex Pharmaceuticals’s revenue was up 39.7% compared to the same quarter last year. During the same period last year, the company posted $0.16 earnings per share. equities analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

In other Vertex Pharmaceuticals news, EVP Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $152.93, for a total value of $324,976.25. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 218,519 shares of company stock worth $31,819,910. 1.80% of the stock is currently owned by corporate insiders.

A number of brokerages have recently commented on VRTX. Needham & Company LLC reaffirmed a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price on the stock. in a research report on Monday, September 4th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Maxim Group reaffirmed a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $173.15.

TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Has $125.06 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/02/new-york-state-common-retirement-fund-has-125-06-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.